Compare Merck & Co., Inc. (MRK) vs Nasdaq100 ETF (QQQ) Price & Performance

Merck & Co., Inc.Trade

Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Nasdaq100 ETF — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Nasdaq100 ETF trades at $708.02. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Nasdaq100 ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.

	MRK	QQQ
Market Cap	$307.25B	—
Sector	Health	—
52-Week High	$129.52	$746.16
52-Week Low	$77.60	$553.88
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Nasdaq100 ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

QQQ

iShares Nasdaq Top 30 ETF outperforms QQQ with a 30% return by focusing on mega-cap tech giants.24/7 Wall Street · 2 days agoBullish REX AI Equity Premium Income ETF offers 36.5% yield but caps upside and may return capital.24/7 Wall Street · 3 days agoNeutral Invesco's IQQQ ETF offers more Nasdaq upside than typical covered-call funds with daily call resets.24/7 Wall Street · 4 days agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.